{"entity":{"id":"phergain","kind":"trial","name":"PHERGain","aka":[],"tldr":"Using an early PET scan to spot responders let a third of women be cured of HER2-positive breast cancer without any chemotherapy.","summary":"PET responders after 2 cycles continued antibodies alone; those achieving pCR (37.9% of the arm) skipped chemotherapy entirely. 3-year iDFS 95.4% in the PET-adapted arm, meeting its co-primary endpoint. Discussed at ESMO Breast 2026 as the model for imaging-guided de-escalation; a phase 3 (PHERGain-2) is underway.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT03161353","url":"https://clinicaltrials.gov/study/NCT03161353"}],"tags":[],"related":[],"indications":["breast-her2-positive"],"sections":[],"technologies":["fdg-pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03161353","phase":"2","setting":"HER2+ early breast cancer: chemotherapy-free trastuzumab + pertuzumab with early 18F-FDG PET response assessment to decide whether chemotherapy is needed","sponsor":"MEDSIR","result":"3-year iDFS 95.4% in the PET-adapted arm; ~1 in 3 spared chemotherapy.","yearReported":2024,"enrolled":377,"enrolledBasis":"registry","outcomes":[{"endpoint":"3-year invasive disease-free survival (PET-adapted arm)","primary":true,"unit":"%","arms":[{"name":"PET-adapted HP ± chemotherapy","n":285,"value":95.4}],"source":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00054-0/fulltext"}],"replication":"Consistent with WSG-ADAPT HER2+/HR- (pCR-guided de-escalation); phase 3 confirmation pending."},"route":"/trials/phergain/","neighbours":{"indication":[{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/"}],"technology":[{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"}]}}